Validation of Clinical Risk Models for Clostridioides difficile <i>-</i> Attributable Outcomes-Reference-Cited by-同舟云学术

Validation of Clinical Risk Models for Clostridioides difficile - Attributable Outcomes

Published:2022-07-19 Issue:7 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Madden Gregory R.¹^ORCID,Petri William A.¹^ORCID,Costa Deiziane V. S.¹,Warren Cirle A.¹,Ma Jennie Z.²,Sifri Costi D.¹³^ORCID

Affiliation:

1. Division of Infectious Diseases & International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA

2. Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA

3. Office of Hospital Epidemiology/Infection Prevention & Control, UVA Health, Charlottesville, Virginia, USA

Abstract

Clostridioides difficile is the leading health care-associated pathogen, leading to substantial morbidity and mortality; however, there is no widely accepted model to predict C. difficile infection severity. Most currently available models perform poorly or were calibrated to predict outcomes that are not clinically relevant.

Funder

HHS | NIH | National Center for Advancing Translational Sciences

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00676-22

Reference63 articles.

1. Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection

2. Impact of Emergency Colectomy on Survival of Patients With Fulminant Clostridium difficile Colitis During an Epidemic Caused by a Hypervirulent Strain

3. Development and Characterization of Mouse Monoclonal Antibodies Specific for Clostridiodes (Clostridium) difficile Lipoteichoic Acid

4. Seres Therapeutics. 2021. Seres therapeutics announces positive topline results from SER-109 phase 3 ECOSPOR III study in recurrent C. difficile infection [Press Release]. https://www.businesswire.com/news/home/20200810005194/en/Seres-Therapeutics-Announces-Positive-Topline-Results-SER-109.

5. Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Clostridioides difficile infection outcomes with explainable machine learning;eBioMedicine;2024-08

2. Validation of clinical risk tools for recurrent Clostridioides difficile infection;Infection Control & Hospital Epidemiology;2024-05-09

3. Derivation and internal validation of the multivariate toxigenic C. difficile diarrhea model and risk score for emergency room and hospitalized patients with diarrhea;Antimicrobial Stewardship & Healthcare Epidemiology;2024

4. Novel Biomarkers, Including tcdB PCR Cycle Threshold, for Predicting Recurrent Clostridioides difficile Infection;Infection and Immunity;2023-04-18

5. A Predictive Model to Identify ComplicatedClostridiodes difficileInfection;Open Forum Infectious Diseases;2023-02-01